anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an auspicious health care pillow comprising a pillow body filled with a plurality of medicine bags. The pillow body consists of a sunken brain part pillow body at the center, neck pillow bodies on the front side and the rear side of the middle, and shoulder pillow bodies on the left side and the right side, wherein the neck pillow bodies and the shoulder pillow bodies are higher than the brain part pillow body. The brain part pillow body is inside provided with a first medicine bag which contains the following powder: rhizoma chuanxiong powder, ganodorma lucidum powder, cassia twig powder, radix astragali powder, flos lonicerae japonicae powder, flos carthami powder, musk powder, mint powder, cortex albiziae powder and herba cistanches powder. Each neck pillow body is inside provided with a second medicine bag which contains the following powder: garden balsam stem powder, lycopodium clavatum powder, rhizoma arisaematis powder, rhizoma cimicifugae powder and piper kadsura powder. The rest of the space in the pillow body is filled with filler which contains buckwheat hulls and tea leaves. The pillow body is inside provided with a plurality of medicine bags with different effects, which are placed at different positions in a targeted manner, so that the pillow is targeted and can achieve a better curing and health care effect.
AIM: The angiotensin-converting enzyme 2 (ACE2) and its homolog, the angiotensin converting enzyme 1 (ACE), are involved in COVID-19 physiopathology. Alterations in the enzymatic structure, expression, and/or activity may influence the risk of infection and severity of disease. For this reason, we aimed to identify different allelic forms of ACE2 G8790A and ACE I/D polymorphisms in a Brazilian cohort and evaluate their impact on ACE and ACE2 activities and their association with COVID-19 susceptibility and severity.
MAIN METHODS: A total of 549 COVID-19-negative and 270 COVID-19-positive participants from Ipaussu, Sao Paulo, Brazil, were recruited. ACE2 and ACE activities were measured by fluorogenic assays using MCA-Ala-Pro-Lys(Dnp) as the substrate for ACE2 and Z-Phe-His-Leu-OH (Z-FHL) and Hippuryl-His-Leu-OH (h-HL) as substrates for ACE. Genomic DNA was extracted from EDTA-peripheral blood, and the regions of the genes containing ACE2 G8790A and ACE I/D polymorphisms were amplified by PCR-restriction fragment length polymorphism and real-time PCR, respectively.
KEY FINDINGS: The G allele of ACE2 G8790A polymorphism and D allele of ACE I/D polymorphism are associated with increased ACE and ACE2 activities. ACE activity ratio (Z-FHL/h-HL), an inflammatory marker, is increased in women with GG genotype and COVID-19-positive diagnosis.
SIGNIFICANCE: For the first time, it was demonstrated that in females, the GG genotype is associated with increased ACE activity ratio (Z-FHL/h-HL) in the COVID-19-positive group. Elevated ACE activity ratio (Z-FHL/h-HL) is highly linked to inflammation and may justify the associations between the G genotype and COVID-19 severity of symptoms and outcomes.
PURPOSE: To obtain a new purine nucleoside derivative having antiviral activity even at low concentrations, having marked inhibitory effect esp. on Rous sarco ma virus and human immunodeficiency virus, and useful as e.g. an enzyme inhibitor for clinical tests. CONSTITUTION: This new compound is expressed by formula I (R<2> and R<3> are each H, a halogen or amino; R<1> is the same as R<2> , OH or methoxy; * denotes an asymmetric carbon atom), e.g. (S)-9-(N-dichloroacetylpyrrolidinylmehtyl) adenine. The compound of formula I is obtained by the following process: D- or L-proline of formula II is reduced into D- or L-prolinol, respectively, and the amino group in the D- or L-prolinol is protected by dichloroacetyl group followed by tosylating the alcoholic OH group in the resultant compound to obtain a compound of formula III (Ts is p-toluenesulfonyl) followed by coupling a purine base with the compound of formula III.
Disclosed herein is a novel antitumor factor, termed Human Monocyte Toxin, obtained by the precise activation of cells of monocyte/macrophage lineage. Monocytes are isolated in the absence of endotoxin by counterflow elutriation. HMT release can be triggered by exposure to low levels of 6-0-stearoyl muramyl dipeptide, lipopolysaccharide, phorbol myristate acetate or other known macrophage activating agents. Triggering results in the rapid release of HMT which requires transcription, translation, and intact secretory apparatus. The requirement for precise control of the triggering agent concentration is disclosed. HMT in serum-free supernatants can be resolved into two distinct species based on molecular sieving employing conventional or HPLC chromatography: minor species of 100-120 Kd, termed alpha, and the predominant form, beta, of 60-70 Kd. Beta-HMT has been further characterized as purified by chromatofocusing and HP ion-exchange LC, which indicate a moderately acidic nature. Beta-HMT demonstrates cytotoxic (cytolytic and/or cytostatic) activity against human and murine cell lines in vitro. Beta-HMT mediated lysis of targets does not involve detectable production H2O2 or O2-, nor can it be blocked by pretreatment of the toxin with TLCK; however, reversible protease inhibitors partially block lysis when coincubated with the target cell and Beta-HMT.
The invention relates to the technical field of molecular biological medicines, in particular to an application of LNCRNA CASC as a hepatic fibrosis biomarker. The invention provides an application of LNCRNA CASC as a hepatic fibrosis biomarker. LNCRNA CASC15 is significantly up-regulated in the serum of patients with liver fibrosis. Proven, LNCRNA CASC has good ability to diagnose liver fibrosis. LNCRNA CASC15 is mainly expressed in the cytoplasm of hepatic fibrosis hepatocytes, and interference LNCRNA CASC can significantly inhibit the expression and secretion of pro-fibrotic cytokine Ihh, thereby inhibiting activation of hepatic stellate cells and improving hepatic fibrosis. Shows that LNCRNA CASC plays an important positive regulation role in the occurrence and development of liver fibrosis, and can provide a new target for clinically treating the liver fibrosis.
A pharmaceutical composition, kit, and method of forcing the reverse transport of cholesterol from peripheral tissues to the liver in vivo while controlling plasma LDL concentrations. The method includes the step of administering a therapeutically effective amount of a multiplicity of large liposomes comprised of phospholipids substantially free of sterol for a treatment period. The method optionally includes the step of periodically assaying plasma LDL concentrations with an assay during the treatment period to assess plasma atherogenic lipoprotein concentrations and obtain an atherogenic lipoprotein profile, and adjusting the administration in response to said profile. The large liposomes are dimensioned larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver so that the liposomes are too large to readily penetrate the fenestrations. The therapeutically effective amounts are in the range of about 10 mg to about 1600 mg phospholipid per kg body weight per dose. A pharmaceutical composition and related kit for mobilizing peripheral cholesterol and sphingomyelin that enters the liver of a subject consisting essentially of liposomes of a size and shape larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver is also provided.
A system for determining adverse effects associated with a substance includes a side-effect recognizer, a relationship extractor, a processor, and a reporting system. The side-effect recognizer utilizes a first recurrent neural network (RNN) to identify a first portion of received data associated with an adverse effect to thereby determine the adverse effect associated with the received data. The relationship extractor utilizes a second RNN to identify a second portion of the received data associated with a substance and a third portion of the received data that indicates a relationship between the substance and the adverse effect to thereby determine the substance associated with the received data and the relationship between the substance and the adverse effect. The processor is in communication with the adverse effect recognizer and the substance relationship extractor and aggregates and relates the adverse effect, substance, and relationship. The reporting system is in communication with the processor and generates a report to convey the relationship between the substance and the adverse effect. Retrieve social media text Determine reliability Identify disease/ symptom phrase Normalizer identified disease/symptom phrase Extract relation between drug and disease/symptom Detect sentiment Aggregate/Report results Fig. 2
Pediatric Use: Melatol™ Pediatric Sleep and Calm Liquid is specifically formulated for pediatric patients and should be used under the guidance of a licensed healthcare practitioner. The safety and efficacy of melatonin for long-term use or in high doses for children have not been fully established. 

Geriatric Use: This formulation is intended for pediatric use, and data on its use in elderly patients are not applicable. 

Hepatic Impairment: Use in children with severe hepatic impairment is not recommended due to altered melatonin metabolism and increased risk of adverse effects. 

Renal Impairment: There is limited data on melatonin use in children with renal impairment. Caution is advised, and a licensed healthcare practitioner should assess the risk-benefit ratio before use.
OBJECTIVES: Therapeutic drug monitoring allows personalized dosing of chemotherapy, but is not well established for capecitabine. The aim of this study was to compare the concentrations of capecitabine and its metabolites obtained simultaneously by microsampling with plasma sampling and their acceptability to patients.
METHODS: Adults taking capecitabine for cancer had paired (duplicate) microsampling at steady state (hour 2 post dose) using Mitra® devices and venous blood samples for analysis. Capecitabine and metabolites were measured using a validated mass spectrometry assay. Correlation between the sampling methods was determined. Patients' preferences were elicited using a Likert numeric rating scale and pain by a Visual Analog Scale (range, 0-10).
KEY FINDINGS: Capecitabine concentrations from 10 patients (60 paired samples) by microsampling and plasma sampling were highly correlated (Pearson correlation: 0.97, Coefficients of determination: 0.94, P < 0.0001). Capecitabine concentrations in capillary sampling were consistently lower than the paired plasma concentration (median capecitabine capillary/plasma concentration ratio = 2851/3846 μg/l 75%). The agreement between sampling matrices showed a 28% bias (95% Cl, 4.02-52.00). Participant ratings showed microsampling was the preferred method by all 10 patients. Most participants reported no pain with microsampling (median 0, range 0-1).
CONCLUSION: Capecitabine concentration measured by microsampling and plasma sampling were highly correlated, but consistently lower in microsampling. Microsampling was the preferred method with minimal pain.
The TORDIA study aims to develop useful clinical guidelines for the care and management of adolescent depression. Adolescents ages 12 to 18, currently taking a prescribed selective serotonin reuptake inhibitor (SSRI) and still experiencing depression, participate in a 12-week randomized treatment study that includes one of four conditions: (1) switching to an alternative SSRI, (2) switching to a different non-SSRI antidepressant, (3) switching to an alternative SSRI and receiving cognitive behavioral therapy (CBT), or (4) switching to a different non-SSRI antidepressant and receiving CBT. This is a double-blind study, which means that neither the participant nor the clinical staff will know which of the three possible medications has been assigned. Participants who respond to the assigned treatment will receive 12 additional weeks of the same treatment. Those who do not appear to be getting better will be offered 12 weeks of an alternative, individualized treatment plan based on each participant's particular needs. All participants will receive follow-up psychiatric evaluations for 12 months after the 12-week continuation phase of the study, regardless of treatment adherence.
Patients will take Buspirone hydrochloride 10mg oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will also report their perceived symptoms of dysphagia during the HRiM. A washout period of two weeks will take place. Afterwards, the second treatment period starts. Patients will take Placebo oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will also be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will again report their perceived symptoms of dysphagia during the HRiM.
In March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak to be a pandemic, and a year later more than 120 000 000 people are confirmed with the disease. The disease has caused more than 2 700 000 deaths globally. Norway has a low mortality rate compared to rest of the world. However, a large proportion (10-33%) of the patients worldwide have reported persistent symptoms, such as dyspnea, reduced exercise capacity, loss of taste/smell and fatigue months after the infection. Persistent symptoms are also found in younger populations and in persons with an initially mild disease.

The intervention will take place at "Helse i Hardanger" (HiH)(Health center in Hardanger, Norway). The participants will stay for a 3 -day rehabilitation intervention, if needed, another 1 or 2-day stay will be offered about a month later. The concentrated treatment will be given by an interdisciplinary team, including doctors, physiotherapists, nutritionists, pharmacists, psychologists/psychiatrists, and nurses. The intervention is an individualized group treatment based on behavioural change.
Renal dysfunction, acute renal failure, osmotic nephropathy, proximal tubular nephropathy, and death may occur upon use of immune globulin intravenous (Human) (IGIV) products. Use VIGIV with caution in patients with pre-existing renal insufficiency and in patients at risk of developing renal insufficiency (including, but not limited to those with diabetes mellitus, age greater than 65 years, volume depletion, paraproteinemia, sepsis, and patients receiving known nephrotoxic drugs), and administer VIGIV at the minimum rate of infusion practicable. In these cases, it is important to ensure that patients are not volume depleted before VIGIV infusion. Do not exceed the recommended infusion rate and follow the infusion schedule closely [see 2.3 Administration]. Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of VIGIV and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing VIGIV.

Most cases of renal insufficiency following administration of IGIV have occurred in patients receiving total doses containing 400 mg/kg of sucrose or greater. VIGIV does not contain sucrose. No prospective data are currently available in patients with risk factors for renal insufficiency to identify a maximum safe dose, concentration, and/or rate of infusion for VIGIV.
BACKGROUND: Living kidney donors are screened pre-donation to estimate the risk of end-stage kidney disease (ESKD). We evaluate Machine Learning (ML) to predict the progression of kidney function deterioration over time using the estimated GFR (eGFR) slope as the target variable.
METHODS: We included 238 living kidney donors who underwent donor nephrectomy. We divided the dataset based on the eGFR slope in the third follow-up year, resulting in 185 donors with an average eGFR slope and 53 donors with an accelerated declining eGFR-slope. We trained three Machine Learning-models (Random Forest [RF], Extreme Gradient Boosting [XG], Support Vector Machine [SVM]) and Logistic Regression (LR) for predictions. Predefined data subsets served for training to explore whether parameters of an ESKD risk score alone suffice or additional clinical and time-zero biopsy parameters enhance predictions. Machine learning-driven feature selection identified the best predictive parameters.
RESULTS: None of the four models classified the eGFR slope with an AUC greater than 0.6 or an F1 score surpassing 0.41 despite training on different data subsets. Following machine learning-driven feature selection and subsequent retraining on these selected features, random forest and extreme gradient boosting outperformed other models, achieving an AUC of 0.66 and an F1 score of 0.44. After feature selection, two predictive donor attributes consistently appeared in all models: smoking-related features and glomerulitis of the Banff Lesion Score.
CONCLUSIONS: Training machine learning-models with distinct predefined data subsets yielded unsatisfactory results. However, the efficacy of random forest and extreme gradient boosting improved when trained exclusively with machine learning-driven selected features, suggesting that the quality, rather than the quantity, of features is crucial for machine learning-model performance. This study offers insights into the application of emerging machine learning-techniques for the screening of living kidney donors.
RATIONALE: As the elderly population grows, the number of joint arthroplasty surgeries is also increasing. Periprosthetic joint infection (PJI) is a postoperative complication that occurs in 1%-2% of the arthroplasties. Once it occurs, PJI is refractory to treatment. Similar symptoms of PJI, including joint synovitis and elevated body temperature, sometimes arise because of crystal arthritis, rheumatoid arthritis, or other inflammatory diseases. Precise diagnosis is essential for determining the optimal treatment strategy.
PATIENT CONCERNS: An 81-year-old female patient with a history of bilateral knee arthroplasty presented with a high fever of 38 °C and was unable to walk due to swelling and pain in the bilateral lower extremities. Infectious conditions, such as cellulitis or PJI, were suspected. Imaging findings revealed bilateral knee joint synovitis with pitting edema around the lower extremities, and cultures of bilateral joint fluids were negative. No crystals were observed in the joint fluid. Laboratory data revealed highly elevated levels of inflammatory marker; however, antinuclear antibodies, including rheumatoid factor and cyclic citrullinated peptide, were not detected.
DIAGNOSES: Based on bilateral synovitis with pitting edema in the lower extremities, in addition to negative culture findings and normal antinuclear antibodies, the diagnosis of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) was made.
INTERVENTIONS: Steroid therapy was performed. The dose was gradually reduced, with the improvement of the symptoms.
OUTCOMES: The inflammatory reaction promptly decreased and then normalized. With improved inflammation, the symptoms of pitting edema, pain in the bilateral lower extremities, and fluid effusion of the knee joints were reduced. She was able to walk without a cane, and her activities of daily living fully recovered.
LESSONS: High fever and synovitis after joint arthroplasty do not necessarily indicate an infectious condition. Clinicians should be familiar with the occurrence of RS3PE, regardless of whether arthroplasty is performed.
The investigators hypothesize that changes in an individual's cognition due to HE-related liver cirrhosis can be stabilized and/or improved through investigational microbiota restoration therapeutic treatment. The main objective of this study is to determine if investigational microbiota restoration therapeutic treatment alters the cognitive function in individuals with cirrhosis who have been previously diagnosed with overt hepatic encephalopathy (HE). Once individuals have one HE episode, they are more likely to experience additional episodes, even after complying with standard of care. The number of HE episodes each study group experiences during the post-treatment follow-up will be compared among treatment groups. It is also anticipated that cognitive improvement will correlate with specific changes in the intestinal microbiota composition of these individuals likely shifting their microbiome away from baseline samples and becoming more like donor samples. Novel blood biomarkers potentially related to episodes of HE will be assessed in individuals before and after treatment.
The present invention relates to a glycoconjugate immunoreactive with Toxoplasma gondii antibodies, (monoclonal) antibodies against these glycoconjugates, and cell lines capable of producing monoclonal antibodies. The invention is further concerned with immunochemical reagents and methods for the detection of T. gondii or antibodies directed agains T. gondii. Furthermore the invention relates to a therapeutic reagent for the inhibition of replication of T. gondii parasites and a method for the production of a live attenuated T. gondii vaccine. It has now been found, and in contrast with earlier publications in this art, that several glycoconjugates are immunoreactive with Toxoplasma gondii specific antibodies comprising a glycan core structure having general formula (I) wherein R1 = Hydrogen, -PO3-CH2-CH2-NH2 (ethanolamine-phosphate), or -PO3-CH2-CH2-NH-X, wherein X = a T. gondii specific antigen; wherein R2 = .alpha.-O-R4, .alpha.(1-4)-O-anhydromannitol or .alpha.(1-4)-O-glucoseamine optionally .alpha.(1-6)-linked to the inositol moiety of a phosphatidylinositol membrane anchor; wherein R3 = a monosaccharide moiety, wherein R4 = Hydrogen or -L-R5, wherein L = a bivalent organic radical and R5 = a functional group that allows coupling to a carrier. A preferred embodiment of the monosaccharide moiety is a hexose moiety, more preferred is a glucose moiety, and most preferred is a glucose moiety which is bonded to the GalNAc-moiety by an .alpha.-1,4 glycosidic bond. It has been found that the glycoconjugates according to the present invention are particularly suitable for diagnosing T. gondii infected humans.
PROBLEM TO BE SOLVED: To obtain the subject composition useful as an additive for imparting a food, a feed or a medicine with the stimulating function against calcium absorption, effectively increasing a calcium absorption rate in intestinal tracts and promoting healthy physiological activity by compounding chitin as an active component. SOLUTION: This composition contains chitin as an active component. The chitin preferably has an average molecular weight of <=100, 000 after a low molecular weight treatment. Chitin is, commonly, treated with a concentrated hydrochloric acid for making the molecular weight small. Concretely, e.g. 5-10% hydrochloric acid is added to chitin of Chinecetes opilis having an average molecular weight of 400,000, the mixture is heated, and subsequently washed with water and neutralized. Then, it is treated in a 10-20% caustic soda solution at 60-90 deg.C to remove protein, again washed with water and neutralized and the precipitate is pulverized after drying. Further, the objective composition is optionally compounded with a calcium salt such as calcium chloride as an active component.